
Turnstone Biologics Corp.
- Jurisdiction
United States - ISIN
US90042W1009 (TSBX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
Profile
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€38.15M - EBIT margin
0.0% - Net income
-€40.50M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |